Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9P0N9

UPID:
TBCD7_HUMAN

ALTERNATIVE NAMES:
Cell migration-inducing protein 23

ALTERNATIVE UPACC:
Q9P0N9; E7EV96; Q2TU37; Q53F44; Q5SZL7; Q86VM8; Q96MB8

BACKGROUND:
The protein TBC1 domain family member 7, also known as Cell migration-inducing protein 23, is integral to the TSC-TBC complex. This complex is essential for the negative regulation of the mTORC1 signaling pathway through its GAP activity towards RHEB. TBC1D7's role is critical in the cellular response to growth factors and glucose, positioning it as a key regulator of cell growth and metabolism.

THERAPEUTIC SIGNIFICANCE:
Given its link to Macrocephaly/megalencephaly syndrome, autosomal recessive, TBC1D7 presents a significant target for therapeutic intervention. The exploration of TBC1D7's function and its regulatory mechanisms offers promising avenues for developing treatments for this genetic disorder, which manifests with significant neurological and physical abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.